©Copyright 2008 Sunil Kumar Aggarwal

Total Page:16

File Type:pdf, Size:1020Kb

©Copyright 2008 Sunil Kumar Aggarwal ©Copyright 2008 Sunil Kumar Aggarwal The Medical Geography of Cannabinoid Botanicals in Washington State: Access, Delivery, and Distress Sunil Kumar Aggarwal A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2008 Program Authorized to Offer Degree: Geography University of Washington Graduate School This is to certify that I have examined this copy of a doctoral dissertation by Sunil Kumar Aggarwal and have found that it is complete and satisfactory in all respects, and that any and all revisions required by the final examining committee have been made. Chair of the Supervisory Committee: ___________________________________________________ Jonathan Mayer Reading Committee: __________________________________________________ Jonathan Mayer _________________________________________________ Richard Morrill ___________________________________________________ Craig ZumBrunnen ___________________________________________________ Gregory Carter ___________________________________________________ Ethan Russo Date:__________________________ In presenting this dissertation in partial fulfillment of the requirements for the doctoral degree at the University of Washington, I agree that the Library shall make its copies freely available for inspection. I further agree that extensive copying of the dissertation is allowable only for scholarly purposes, consistent with “fair use” as prescribed in the U.S. Copyright Law. Requests for copying or reproduction of this dissertation may be referred to ProQuest Information and Learning, 300 North Zeeb Road, Ann Arbor, MI 48106-1346, 1-800-521-0600, to whom the author has granted “the right to reproduce and sell (a) copies of the manuscript in microform and/or (b) printed copies of the manuscript made from microform.” Signature________________________ Date____________________________ University of Washington Abstract The Medical Geography of Cannabinoid Botanicals in Washington State: Access, Delivery, and Distress Sunil Kumar Aggarwal Chair of the Supervisory Committee: Professor Jonathan Mayer Geography Though rendered dormant by a post-1937 Cannabis sativa L. prohibition, the emerging field of cannabinoid medicine is growing in the United States as ever greater numbers of physicians become educated about the physiologic importance of the endogenous cannabinoid system and about the wide safety margins and broad clinical efficacies of cannabinoid drugs, available in both purely botanical and purely chemical varieties and useful for managing pain and other conditions in the growing chronically and critically ill patient population. Research presented here is focused on medical access and delivery of cannabinoid botanicals in Washington State and seeks to map the geography of this developing cannabinoid medical care system by taking medical geographic “snapshots” of two purposefully chosen locations: a rural clinic site in Washington State where patients currently access cannabinoid botanicals for medical use in the treatment of chronic pain syndromes with acceptable safety under medical supervision and another site where qualifying patients are delivered environmentally- culled cannabinoid botanicals. At the former site, retrospective chart reviews were conducted with 139 patients with chronic pain, and at the latter site, a convenience sample of 37 qualifying patients delivered a monoclonal lot of cannabinoid botanical medicine were prospectively studied using standard and tailored survey instruments. A political ecology of disease approach was employed to rationalize and depathologize patients’ mental distress at potentially facing possession-related legal problems due to their consumption of the still-contraband biota. Results provide quantitative and qualitative insight into the frail health status in both samples of qualifying patients and give a grounded understanding of the lengths that patients and care providers go, despite multiple hurdles, to access and deliver treatment with cannabinoid botanicals that relieves patients’ diverse symptoms and improves their health-related quality-of- life. TABLE OF CONTENTS Page List of Figures................................................................................................................. iii List of Tables ...................................................................................................................iv Introduction: Medical Geography and the Phenomenon of Hempen Cannabinergy........1 References for Introduction ................................................................................20 The Medical Geography of Cannabinoid Botanicals in Washington State I: Characteristics of Patients with Chronic Pain Accessing Treatment at a Rural Clinic.....................................................................................................................25 Introduction to Cannabinoid Medicine in the US...............................................25 Contesting Cannabinoid Botanical Medicines....................................................31 Authorizing the Medical Use of Cannabinoid Botanicals in Washington State................................................................................................36 Study Design and Procedures .............................................................................40 Results.................................................................................................................44 Conclusion ..........................................................................................................49 References for I...................................................................................................56 The Medical Geography of Cannabinoid Botanicals in Washington State II: Subjective Health Status of Qualifying Patients Delivered a Clonal Lot of Maturated Germplasm ....................................................................................................67 Introduction........................................................................................................67 Contesting Cannabinoid Botanical Medicines and the Human-Environment Relationship .......................................................................................................69 Study Background .............................................................................................76 Study Design......................................................................................................81 Study Procedures ...............................................................................................83 Complementary and Alternative Cannabinoid Botanical Medicines Community Clinic Characteristics.....................................................................85 Subjective Health Status in a Convenience Sample of Qualifying Patients......88 Prospective Health Data from Returned Take-Home Materials........................95 Cost of Keeping a Lot of Cannabinoid Botanical Medicine Stocked and Deliverable.........................................................................................................96 Discussion..........................................................................................................97 Conclusion .......................................................................................................100 References for II ..............................................................................................130 The Medical Geography of Cannabinoid Botanicals in Washington State III: Contraband Psychoactive Biota Consumption and the Political Ecology of Mental Distress at Facing Possession-Related Legal Problems ...................................141 Tracing the Roots of a Critical Political Ecology of Disease ..........................141 Psychoactive Biotic Substances and the Political Ecology of Mental Distress ................................................................................................145 Substance-Related Disorders Diagnostics and Possession-Related Legal Problems ..........................................................................................................152 i Banning Biota and Sowing the Seeds of Distress............................................159 Asserting the Human Right to Health..............................................................166 Therapeutic Cannabis Users’ Mental Distress at Facing Possession-Related Legal Problems: a Local Case Study...............................................................168 Discussion........................................................................................................180 Conclusion .......................................................................................................185 References for III.............................................................................................195 Conclusion: Pain Relief on Pain of Death—When Worldviews Collide .....................205 References for Conclusion...............................................................................209 Bibliography .................................................................................................................211 Appendix A: Chart Review Data..................................................................................273 Appendix B: Interview Script and Survey Instruments................................................302 Appendix C: Consent Form..........................................................................................357
Recommended publications
  • EMCDDA Cannabis Reader
    ISSN 1606-1691 A cannabis reader: global issues and local experiences 05 06 15 TD-32-07-001-EN-C About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The Centre’s publications are a prime source of information for a wide range of audiences including policy-makers and their advisers; professionals and researchers working in the drugs field; and, more broadly, the media and general public. EMCDDA monographs are comprehensive scientific publications containing thematic papers prepared in the context of the Centre’s activities. Topics cover a wide range of issues relating to science, policy, epidemiology and best EMCDDA practice. MONOGRAPHS A cannabis reader: global issues and local experiences Price (excluding VAT) in Luxembourg: EUR 20 per volume MONOGRAPHS EMCDDA VOL. I VOL. 8 8 I VOLUME EMCDDA MONOGRAPHS A cannabis reader: global issues and local experiences Perspectives on cannabis controversies, treatment and regulation in Europe Editors Sharon Rödner Sznitman, Börje Olsson, Robin Room 8 I VOLUME Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document.
    [Show full text]
  • Medicinal Use of Cannabis 3Rd Edition
    M E M O R A N D U M Medicinal use of Cannabis 3rd edition 2015 04/12/2015 Medicines Control & Inspection File no.2013113424/ Axel Heides Gade 1 DK-2300 Copenhagen S Frank Bøgh Madsen [email protected] Email: [email protected] Page 2 04/12/2015 Danish Medicines Agency Contents 1. Introduction ................................................................................................ 3 2. The body's own cannabinoids and receptors .............................................. 3 3. Knowledge about intoxicating and harmful effects and the prevalence of Cannabis......................................................................................................... 4 3.1. The Dutch Ministry of Health's brochure about side effects of medicinal use of Cannabis .......................................................................................... 5 4. Rules about Cannabis as a euphoriant substance ....................................... 6 4.1. List A – Cannabis ............................................................................... 6 4.2. List B – THC in pure form and other cannabinoids ............................ 7 4.3. CBD – in pure form or in hemp products ............................................ 8 5. Positive effects of medicines containing active substances from Cannabis and clinical trials ............................................................................................ 8 5.1. Other scientific evidence about Cannabis and cannabinoids ............ 10 6. Rules about medicines requiring a marketing authorisation (Sativex®)
    [Show full text]
  • MEDICAL CANNABIS in EUROPE: the Markets & Opportunities SECOND EDITION
    MEDICAL CANNABIS IN EUROPE: The Markets & Opportunities SECOND EDITION In-depth look at key European markets and the regulations companies need to understand to tap these revenue opportunities © 2020 Anne Holland Ventures Inc. All Rights Reserved Medical cannabis for German patients We purchase and import EU-GMP medical cannabis into Germany and sell to pharmaceutical wholesalers who supply to pharmacists Subscribe to our newsletter at amp-eu.com/learnmore Medical Cannabis in Europe: The Markets and Opportunity mjbizdaily.com/intl TABLE OF CONTENTS WLECOME LETTER 5 EU MARKET AT A GLANCE 9 GERMANY 14 ITALY 43 THE NETHERLANDS 55 DENMARK 65 CZECH REPUBLIC 74 AUSTRIA AND SWITZERLAND 78 OTHER SMALL MARKETS 80 3 Copyright 2020, Marijuana Business Daily, a division of Anne Holland Ventures Inc. You may NOT copy this report, or make public the data and facts contained herein, in part or in whole. For more copies or editorial permissions, contact [email protected] or call 720.213.5992 ext. 1. RESEARCH DRIVEN LEDs for Compact Plants with High THC/CBD Outputs UV-A Enriched Spectrum for Increased Cannabinoid Production GACP/GMP Facility Suitable Since 2009 we have been committed to creating the best LED grow lights on the market so as to enable growers to increase yields, quality and energy savings. With the largest patent portfolio in the cannabis lighting industry, we are the pioneers of the high quality horticultural LED solutions. 31% 16% 28% more more total more compact plants cannabinoid flowers yield ...than with HPS. 7% 6% 4% more more total more compact plants cannabinoid THC yield ...than with competitor’s LEDs.
    [Show full text]
  • Current Barriers to Patient Access to Medicinal Cannabis in Australia
    The Senate Community Affairs References Committee Current barriers to patient access to medicinal cannabis in Australia March 2020 © Commonwealth of Australia 2020 ISBN 978-1-76093-059-2 (Printed Version) ISBN 978-1-76093-059-2 (HTML Version) This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 Australia License. The details of this licence are available on the Creative Commons website: http://creativecommons.org/licenses/by-nc-nd/3.0/au/. Printed by the Senate Printing Unit, Parliament House, Canberra Committee Members Chair Senator Rachel Siewert AG, WA Deputy Chair Senator Wendy Askew LP, TAS Members Senator Catryna Bilyk ALP, TAS (from 5 February 2020) Senator Raff Ciccone ALP, VIC (from 5 December 2019 to 5 February 2020) Senator Hollie Hughes LP, NSW Senator Malarndirri McCarthy ALP, NT Senator Anne Urquhart ALP, TAS Participating Members Senator Catryna Bilyk ALP, TAS (until 5 February 2020) Senator Richard Di Natale AG, VIC Former Members Senator Deborah O'Neill ALP, NSW (until 5 December 2019) Secretariat Jeanette Radcliffe, Committee Secretary Apolline Kohen, Principal Research Officer Kathleen McGarry, Acting Senior Research Officer Carol Stewart, Administrative Officer PO Box 6100 Parliament House Canberra ACT 2600 Phone: 02 6277 3515 Fax: 02 6277 5829 E-mail: [email protected] Internet: www.aph.gov.au/senate_ca iii Table of Contents Committee Members ........................................................................................................................ iii
    [Show full text]
  • EMCDDA INSIGHTS — an Overview of Cannabis Potency in Europe
    EMCDDA INSIGHTS An overview of cannabis potency in Europe Prepared by Leslie A. King EMCDDA project group Chloé Carpentier Paul Griffiths 6 Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright. The EMCDDA accepts no responsibility or liability for any consequences arising from the use of the data contained in this document. The contents of this publication do not necessarily reflect the official opinions of the EMCDDA’s partners, any EU Member State or any agency or institution of the European Union or European Communities. A great deal of additional information on the European Union is available on the Internet. It can be accessed through the Europa server (http://europa.eu.int). Europe Direct is a service to help you find answers to your questions about the European Union New freephone number: 00 800 6 7 8 9 10 11 Cataloguing data can be found at the end of this publication. Luxembourg: Office for Official Publications of the European Communities, 2004 ISBN 92-9168-184-9 © European Monitoring Centre for Drugs and Drug Addiction, 2004 Reproduction is authorised provided the source is acknowledged. Printed in Belgium PRINTED ON WHITE CHLORINE-FREE PAPER Rua da Cruz de Santa Apolónia, 23-25, 1149-045 Lisbon, Portugal Tel. (351) 218 11 30 00 • Fax (351) 218 13 17 11 [email protected] • http://www.emcdda.eu.int Contents Foreword 5 Acknowledgements 7 Preface 9 Executive summary 13 Chapter 1: Introduction 17 Chapter 2: Analytical aspects 23 Chapter 3: Trends in cannabis potency in Europe 29 Chapter 4: The cannabis market in Europe: potency considerations 43 Chapter 5: Trends in cannabis potency in other countries 51 Chapter 6: Identification of information gaps, priorities for future research and recommendations 55 Glossary 61 References 65 Contact details 71 Foreword Cannabis is the illegal substance most commonly used in all countries of the European Union, with many countries reporting lifetime experience of the drug by more than 20 % of the general population.
    [Show full text]
  • 2020 Global Report on Cannabis Policy
    2020 Global Report on Cannabis Policy October 2020 2 i Contents INTRODUCTION II U.S.A. - OREGON 101 BRAZIL 1 U.S.A. - WASHINGTON 106 CANADA 12 OUR MEMBERS 111 CHINA 20 CONTRIBUTORS 112 COLOMBIA 25 DENMARK 31 ENGLAND 37 GERMANY 45 ITALY 51 PARAGUAY 56 PERU 60 SLOVENIA 68 SOUTH AFRICA 74 SPAIN 79 THAILAND 85 URUGUAY 90 U.S.A. - CALIFORNIA 96 Global Report on Cannabis Policy theworldlawgroup.com 3 ii WLG CANNABIS GUIDE INTRODUCTION We are very pleased to announce the release of the World Law Group (“WLG”) Cannabis Guide 2020. In recent years, cannabis and products with cannabis components are one of the “hot topics” in the life sciences industry. Many countries now allow the medical use of cannabis to treat numerous conditions, including chronic pain, cancer, multiple sclerosis, and many others. Additionally, more and more countries have recently allowed the recreational use of cannabis. Finally, hemp (cannabis grown without mind-altering substances), is another burgeoning industry worldwide. Though there are international treaties in place, the production, distribution, and consumption of controlled substances (including cannabis) are still traditionally regulated by each country individually (even within the EU). Some countries still consider cannabis a dangerous illicit substance. Thus the legal landscape on cannabis and cannabis products is very fragmented and complicated, making it hard to get involved in the cannabis industry. The aim of this guide is to provide a brief overview of laws and policies regarding the use of cannabis in various jurisdictions. It briefly outlines information on the most important legal issues, from relevant legislation and general information to special requirements and risks.
    [Show full text]
  • Cannabis Regulation and Cannabis Derived Products
    Cannabis Regulation and Cannabis Derived Products Austria FPLP 6 Brazil Felsberg Advogados 21 Colombia MTA 23 Germany Rittershaus 35 Gibraltar Hassans International Law Firm 46 Hong Kong Charltons 50 India Dua Associates 57 Israel AYR 81 Malta DF Advocates 86 Netherlands Ekelmans & Meijer Advocaten 91 Portugal Sérvulo & Associados 94 South Korea Barun Law 102 Spain Lopez Ibor Abogados 105 Turkey Gün & Partners 108 UK Mishcon de Reya 112 Ukraine Asters 117 Uruguay Hughes & Hughes 120 USA Bell Nunnally 123 USA Carter Ledyard & Milburn 144 AUSTRIA Polak & Partners Rechtsanwälte Gmb 1. What regulatory frameworks are relevant to medical and recreational cannabis and the cultivation, manufacture, distribution etc of cannabis and cannabinoids in Austria? 1.1. Narcotics framework In Austria, cannabis is subject to the provisions of the Austrian Narcotic Substances Act (Bundesgesetz über Suchtgifte, psychotrope Sto!e und Drogenausgangssto!e; Suchtmittelgesetz (SMG)). The classification of cannabis as a narcotic substance is based on the UN Single Convention on Narcotic Drugs. As required by Article 36 of the UN Single Convention on Narcotic Drugs, the cultivation, production, manufacture, extraction, preparation, possession, o!ering, o!ering for sale, distribution, purchase, sale, delivery on any terms whatsoever, brokerage, dispatch, dispatch in transit, transport, importation and exportation of drugs contrary to the provisions of this Convention shall constitute punishable o!ences. This Article was implemented via Section 27 et seqq in Austria as follows: a) § 27 (1) SMG – Illegal handling of narcotics (basic criminal o!ence): It is a punishable o!ence to acquire, possess, produce, transport, import or export, or to o!er to, give to or procure for a third person, cannabis containing more than 0.3% tetrahydrocannabinol (THC).
    [Show full text]
  • Cannabis Legal & Regulatory Update
    NEWSLETTER Cannabis Legal & Regulatory Update September ­ December 2019 PDF version CONTENT 1. HIGHLIGHTS 2. LATEST LAWS, REGULATORY GUIDANCE AND ENFORCEMENT ACTIONS 2.1. Medical Cannabis 2.2. Well­Being Cannabis 2.3. Recreational Cannabis 3. SELECTED INDUSTRY AND MARKET NEWS The A&O View 2019 was a momentous year for the cannabis industry – this emerging industry is so fast­ moving that it is said to live in dog years. The medical benefits of cannabis and its derivatives have received green light from the international community. During the last quarter of 2019, the first EU­wide marketing authorisation for a cannabis­derived medicinal product was granted by the European Medicines Agency, France continued gearing up for the implementation of its medical cannabis pilot programme, and an increasing number of countries started reimbursing patients for cannabis­based products. National courts (in the UK) have started showing lenience for home­growing cannabis for medical purposes. Meanwhile Big Pharma is – not only – watching and swiftly expanding its cannabis patent portfolio. The CBD landscape, on the other hand, is still characterised by fifty shades of grey. While CBD­based edibles have become a hot commodity on the EU market, the first national regulators and courts (in Finland, Germany…) have now officially banned such products for lack of novel foods authorisation. Will EFSA finally break the deafening silence, and provide some much needed practical guidance, now that a second novel food application – for synthesised CBD – has been filed? If it depends on the European Commission, the EU will unfortunately not wholeheartedly support the – scientifically sensible – WHO recommendations at the next meeting of the Commission on Narcotic Drugs.
    [Show full text]
  • The European Cannabis Reporttm
    The European Cannabis Report TM July 2018 3rd Edition TM The European Cannabis Report | Table of Contents 2 3rd Edition Table of Contents Introduction 6 Lead Sponsor Foreword 7 Executive Summary 9 An Introduction to Medical Cannabis 10 Market Size 12 Market Overview Methodology Medical Recreational Industrial Legislation 15 Overview Medical Recreational Industrial The Process of Legal Reform Regulation 20 Overview The United Nations Medical Cannabis Programs Cannabis Agencies Healthcare 22 Potential Qualifying Conditions Healthcare Analysis Commercial Opportunities 23 Corporate Social Responsibility 25 Key Countries 28 Cannabis remains illegal in most European countries so please reference your local laws in relation to medical or recreational use. This report has been compiled for informational purposes only. It should not be construed as a research report for investment, legal, medical, health or tax advice. © 2018 PP Intelligence LTD. TM The European Cannabis Report | Table of Contents 3 3rd Edition Table of Contents Germany 29 Czech Republic 54 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel 6. European Panel Spain 35 France 59 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6. European Panel 6. European Panel The Netherlands 40 Ireland 64 1. Market Overview 1. Market Overview 2. Regulatory Environment 2. Regulatory Environment 3. Healthcare Analysis 3. Healthcare Analysis 4. Commercial Opportunities 4. Commercial Opportunities 5. Consumption 5. Consumption 6.
    [Show full text]
  • EMCDDA Insights: Cannabis Production and Markets in Europe
    ISSN 1606-1683 ISSN TD -XD -12- 012- EN - C productionCannabis and markets Europe in About the EMCDDA The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is one of the European Union’s decentralised agencies. Established in 1993 and based in Lisbon, it is the central source of comprehensive information on drugs and drug addiction in Europe. The EMCDDA collects, analyses and disseminates factual, objective, reliable and comparable information on drugs and drug addiction. In doing so, it provides its audiences with an evidence-based picture of the drug phenomenon at European level. The EMCDDA’s Insights are volumes conveying the findings of study and research on topical issues in the drugs field. EMCDDA INSIGHTS EMCDDA Price (excluding VAT) in Luxembourg: EUR 15 INSIGHTS Cannabis production and markets in Europe 12 12 How to obtain EU publications Free publications: • via EU Bookshop (http://bookshop.europa.eu); • at the European Union’s representations or delegations. You can obtain their contact details on the Internet (http://ec.europa.eu) or by sending a fax to +352 2929-42758. Priced publications: • via EU Bookshop (http://bookshop.europa.eu). Priced subscriptions (e.g. annual series of the Official Journal of the European Union and reports of cases before the Court of Justice of the European Union): • via one of the sales agents of the Publications Office of the European Union (http://publications.europa.eu/others/agents/index_en.htm). EMCDDA INSIGHTS Cannabis production and markets in Europe 12 Legal notice This publication of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) is protected by copyright.
    [Show full text]